Johnson & Johnson : 2023 Third-Quarter Press Release & Suppl

Media contact:




Investor contact:




...

Related Keywords

Joaquin Duato , Tesia Williams , Jessica Moore , European Medicines Agency Seeking Approval , Exchange Commission , Drug Administration Seeking , European Academy Of Dermatology , Finalizes Separation Of Kenvue Inc , Johnson Announces Final Results Of Exchange , Janssen Highlights Latest Research , Consumer Health Company , Trueref Technology For Mapping , Nipocalimab Clinical Development Program To Address Unmet , Consumer Health , Interventional Solutions , Johnson , Abiomed , Janssen To Highlight Latest Research , European Society Of Retina Specialists , European Commission Approves , European Medicines Agency , Company Consumer Health , Chief Executive , Innovative Medicine , Operational Sales , Net Earnings , Infectious Diseases , General Surgery , New Announcements , Current Reports , Quarterly Reports , Annual Reports , Investor Relations , Multiple Atrial Fibrillation Ablation Products , First In Class Bispecific Therapy , Heavily Pretreated Multiple Myeloma , Novel Bispecific Therapy , Refractory Multiple Myeloma , Commission Approves Reduced Dosing Frequency , Bispecific Antibody , Submits Application , First Line Treatment , Adult Patients , Advanced Non Small Cell , Submits Supplemental New Drug Application , Drug Administration Seeking Full , Locally Advanced , Submits Marketing Authorisation Application , Metastatic Urothelial Cancer , Abiraterone Acetate , First And Only Dual Action Tablet , Highlight Latest Research , Nipocalimab Clinical Development Program , Address Unmet , Myasthenia Gravis , Define New Standards , Solid Tumor Cancers , Severely Active Crohn , Highlights Latest Research , Investigational Targeted Oral Peptide , Isevere Plaque Psoriasis , European Academy , Meets Primary Endpoint Resulting , Statistically Significant , Meaningful Improvement , Progression Free Survival , Versus Osimertinib , Mutatednon Small Cell Lung Cancer , Meets Dual Primary Endpoint Resulting , Cell Lung Cancer , Disease Progression , Free Survival , Previously Treated , Mutated Advanced Non Small Cell Lung , Highlight Latest Advances , Retina Portfolio , European Society , Retina Specialists , Webster Launches , Johnson Announces Final Results , Exchange Offer , Finalizes Separation , Johnson Announces Updated Financials , Following Completion , Johnson Marks New Era , Global Healthcare Company , Updated Visual Identity , Reported Sales , Shares Outstanding , Euro Average Rate , Average Shares Outstanding , Financial Measures , Investors Concerning Forward Looking Statements , Private Securities Litigation Reform Act , New Consumer Health Company , Annual Report , Note Regarding Forward Looking , Markets ,